AnaptysBio Inc
ANAB50.010USD
-0.030-0.06%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.38BMarket Cap
LossP/E TTM
More Details of AnaptysBio Inc Company
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
AnaptysBio Inc Info
Ticker SymbolANAB
Company nameAnaptysBio Inc
IPO dateJan 26, 2017
CEOFaga (Daniel R)
Number of employees136
Security typeOrdinary Share
Fiscal year-endJan 26
Address10770 Wateridge Circle, Suite 210
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18583626295
Websitehttps://www.anaptysbio.com/
Ticker SymbolANAB
IPO dateJan 26, 2017
CEOFaga (Daniel R)
Company Executives of AnaptysBio Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel R. Faga
Mr. Daniel R. Faga
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
436.47K
+0.39%
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
63.34K
+10.52%
Dr. Rita Jain, M.D.
Dr. Rita Jain, M.D.
Independent Director
Independent Director
11.86K
+161.67%
Mr. John A. Orwin
Mr. John A. Orwin
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
10.66K
+13.88%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
9.93K
+154.62%
Mr. Eric Joseph Loumeau, J.D.
Mr. Eric Joseph Loumeau, J.D.
Chief Legal Officer
Chief Legal Officer
6.12K
-34.61%
Mr. Hollings C. Renton
Mr. Hollings C. Renton
Independent Director
Independent Director
4.96K
--
Mr. Dennis M. Mulroy, CPA
Mr. Dennis M. Mulroy, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Paul F. Lizzul, M.D., Ph.D.
Dr. Paul F. Lizzul, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Dennis Fenton, Ph.D.
Dr. Dennis Fenton, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel R. Faga
Mr. Daniel R. Faga
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
436.47K
+0.39%
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
63.34K
+10.52%
Dr. Rita Jain, M.D.
Dr. Rita Jain, M.D.
Independent Director
Independent Director
11.86K
+161.67%
Mr. John A. Orwin
Mr. John A. Orwin
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
10.66K
+13.88%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
9.93K
+154.62%
Mr. Eric Joseph Loumeau, J.D.
Mr. Eric Joseph Loumeau, J.D.
Chief Legal Officer
Chief Legal Officer
6.12K
-34.61%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
EcoR1 Capital, LLC
28.46%
Point72 Asset Management, L.P.
8.18%
Millennium Management LLC
5.49%
The Vanguard Group, Inc.
5.32%
BlackRock Institutional Trust Company, N.A.
5.31%
Other
47.24%
Shareholders
Shareholders
Proportion
EcoR1 Capital, LLC
28.46%
Point72 Asset Management, L.P.
8.18%
Millennium Management LLC
5.49%
The Vanguard Group, Inc.
5.32%
BlackRock Institutional Trust Company, N.A.
5.31%
Other
47.24%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
48.20%
Hedge Fund
33.13%
Investment Advisor
24.49%
Research Firm
7.44%
Corporation
2.97%
Individual Investor
2.85%
Venture Capital
0.98%
Bank and Trust
0.20%
Pension Fund
0.13%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
361
31.62M
161.07%
+8.38K
2025Q3
371
31.61M
166.22%
-3.28M
2025Q2
361
36.31M
176.56%
-3.15M
2025Q1
348
39.44M
156.40%
-8.08M
2024Q4
333
34.84M
133.20%
+863.79K
2024Q3
319
33.94M
120.27%
+3.50M
2024Q2
307
30.16M
131.57%
-496.59K
2024Q1
304
29.48M
131.02%
-6.31M
2023Q4
304
30.59M
131.14%
-22.17K
2023Q3
305
31.48M
131.45%
+54.35K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
EcoR1 Capital, LLC
7.88M
28.15%
--
--
Jun 30, 2025
Point72 Asset Management, L.P.
2.47M
8.84%
+106.50K
+4.50%
Jun 30, 2025
Millennium Management LLC
1.43M
5.1%
+1.22M
+601.03%
Sep 16, 2025
The Vanguard Group, Inc.
1.53M
5.48%
+20.23K
+1.34%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.55M
5.52%
-286.42K
-15.63%
Jun 30, 2025
Tang Capital Management, LLC
1.33M
4.75%
-214.27K
-13.87%
Jun 30, 2025
Morgan Stanley & Co. LLC
1.64M
5.85%
+1.16M
+245.80%
Jun 30, 2025
First Light Asset Management, LLC
2.13M
7.62%
-1.41M
-39.71%
Jul 31, 2025
State Street Investment Management (US)
821.03K
2.93%
-39.69K
-4.61%
Jun 30, 2025
Assenagon Asset Management S.A.
839.93K
3%
+822.98K
+4852.73%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.06%
Tema Oncology ETF
1.04%
ALPS Medical Breakthroughs ETF
0.42%
State Street SPDR S&P Biotech ETF
0.27%
Direxion Daily S&P Biotech Bull 3X Shares
0.17%
ProShares Ultra Nasdaq Biotechnology
0.14%
iShares Micro-Cap ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.1%
iShares Biotechnology ETF
0.08%
Motley Fool Next Index ETF
0.05%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.06%
Tema Oncology ETF
Proportion1.04%
ALPS Medical Breakthroughs ETF
Proportion0.42%
State Street SPDR S&P Biotech ETF
Proportion0.27%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.17%
ProShares Ultra Nasdaq Biotechnology
Proportion0.14%
iShares Micro-Cap ETF
Proportion0.14%
Invesco Nasdaq Biotechnology ETF
Proportion0.1%
iShares Biotechnology ETF
Proportion0.08%
Motley Fool Next Index ETF
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of AnaptysBio Inc?
The top five shareholders of AnaptysBio Inc are:
EcoR1 Capital, LLC holds 7.88M shares, accounting for 28.15% of the total shares.
Point72 Asset Management, L.P. holds 2.47M shares, accounting for 8.84% of the total shares.
Millennium Management LLC holds 1.43M shares, accounting for 5.10% of the total shares.
The Vanguard Group, Inc. holds 1.53M shares, accounting for 5.48% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.55M shares, accounting for 5.52% of the total shares.
EcoR1 Capital, LLC holds 7.88M shares, accounting for 28.15% of the total shares.
Point72 Asset Management, L.P. holds 2.47M shares, accounting for 8.84% of the total shares.
Millennium Management LLC holds 1.43M shares, accounting for 5.10% of the total shares.
The Vanguard Group, Inc. holds 1.53M shares, accounting for 5.48% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.55M shares, accounting for 5.52% of the total shares.
What are the top three shareholder types of AnaptysBio Inc?
The top three shareholder types of AnaptysBio Inc are:
EcoR1 Capital, LLC
Point72 Asset Management, L.P.
Millennium Management LLC
EcoR1 Capital, LLC
Point72 Asset Management, L.P.
Millennium Management LLC
How many institutions hold shares of AnaptysBio Inc (ANAB)?
As of 2025Q4, 361 institutions hold shares of AnaptysBio Inc, with a combined market value of approximately 31.62M, accounting for 161.07% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -5.15%.
What is the biggest source of revenue for AnaptysBio Inc?
In --, the -- business generated the highest revenue for AnaptysBio Inc, amounting to -- and accounting for --% of total revenue.
